Mucormycosis Treatment Guidelines

First-Line Antifungal Therapy

The European Society of Clinical Microbiology and Infectious Diseases recommends liposomal amphotericin B (L-AmB) at 5-10 mg/kg/day as the first-line treatment for all forms of mucormycosis 2, 3
The full daily dose of L-AmB should be administered from the first treatment day rather than slowly increasing over several days 2
For CNS involvement, L-AmB at 10 mg/kg/day is recommended based on animal models and clinical observations 2
Amphotericin B lipid complex (ABLC) at 5 mg/kg/day can be used as an alternative for patients without CNS involvement 2, 3
Isavuconazole is recommended with moderate strength as an alternative first-line treatment for mucormycosis 2, 3

Surgical debridement or resection should be combined with antifungal therapy whenever possible 1, 2, 4
Surgery is strongly recommended (AII evidence) for rhino-orbito-cerebral, soft tissue, and localized pulmonary lesions 1, 5
For disseminated disease, surgical intervention should be considered on a case-by-case basis (BII evidence) 1, 5

Control of underlying conditions is critical and strongly recommended (AII evidence) 1, 6
Rapid correction of metabolic abnormalities is mandatory in uncontrolled diabetes 6, 7
Discontinuation or tapering of corticosteroids when feasible 6, 7
Reduction of immunosuppressive therapy when possible 1, 7
Use of hematopoietic growth factors (G-CSF, GM-CSF) if neutropenia is present 1, 6

Immediate treatment initiation is strongly recommended in any immunocompromised patient with suspected mucormycosis 2, 4
Diagnostic procedures should not delay therapy initiation 2
In patients with renal impairment, L-AmB is preferred over conventional amphotericin B formulations 3
For patients with previous mucormycosis, surgical resection and continuation or restart of the last effective antifungal is strongly recommended for secondary prophylaxis 2

Delaying treatment initiation significantly increases mortality - studies show a two-fold increase in 12-week mortality when treatment is delayed for 6 or more days 4
Underdosing amphotericin B formulations may lead to treatment failure - ensure adequate dosing from the start 2, 3
Renal toxicity may occur with high-dose L-AmB (10 mg/kg/day), but is mostly reversible; doses should not be reduced below 5 mg/kg/day unless absolutely necessary 2, 3